After 12 years of various studies and achieving extraordinary results in the human phase, these services have been institutionalized in this company for the treatment of female infertility based on the requirements of the Food and Drug Administration.Read More
Stem cell therapy based on the knowledge of experts in this field, using the latest science in the world and having the largest infertility treatment center with menstrual blood-derived stem cells, to help the growing medical processRead More
After achieving the desired results on the safety and effectiveness of stem cells in the treatment of various diseases, including for the first time in Asia, the company has treated infertility in women with severe ovarian reserve using menstrual blood stem cells.Read More
Zaya Novin Bioengineering Company was established in 1400 by utilizing and relying on the knowledge and experience of experts in the field of cell therapy and infertility treatment in order to provide cell therapy services, production of various solutions and infertility treatment environments.Read More
What is our service?
- View All
- Infertility treatment
- Cell therapy
One of the goals of Zaya Novin collection is to provide a new service to women
Stem cell safety and efficacy in the treatment of various diseases, including the treatment of infertility in women with severely reduced ovarian reserve using menstrual blood stem cells
The treatment of female infertility is based on the requirements of the Food and Drug Administration in this company.
For the treatment of female infertility based on the requirements of the Food and Drug Administration is established in this company.
Minimize infertility problems and maintain childbearing potential with modern methods in Iran and the region to improve health and health services
Menstrual blood-derived infertility treatment center to assist in the growing process of restorative medicine and cell-based therapies
Why we are your choice
New treatment experience
Let's start a new foundation
Newborn New Miracle